Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17396793 | 0.98 | CYP11B1 (0.50) | CYP11B1CYP11B2HSP90AB1KDM4ESMN1; SMN2 | |
| SCHEMBL1922339 | 0.83 | CYP1A2 (0.52) | KDM4ESMN1; SMN2MAPTHTTCYP1A2 | |
| SCHEMBL751036 | 0.83 | CYP11B1 (0.48) | CYP11B1CYP11B2KDM4ESMN1; SMN2MAPT | |
| SCHEMBL3669289 | 0.82 | CYP11B1 (0.54) | CYP11B1CYP11B2HSP90AB1KDM4ESMN1; SMN2 | |
| SCHEMBL1502754 | 0.81 | CASP3 (0.42) | KDM4ESMN1; SMN2MAPTHTTCYP1A2 | |
| SCHEMBL12028352 | 0.81 | CYP11B1 (0.52) | CYP11B1CYP11B2HSP90AB1KDM4ESMN1; SMN2 | |
| SCHEMBL12807583 | 0.81 | HSP90AB1 (0.65) | CYP11B1CYP11B2HSP90AB1KDM4ESMN1; SMN2 | |
| SCHEMBL10174453 | 0.81 | CYP11B1 (0.56) | CYP11B1CYP11B2HSP90AB1KDM4ESMN1; SMN2 | |
| SCHEMBL3372179 | 0.80 | HTT (0.46) | KDM4ESMN1; SMN2MAPTHTTCYP1A2 | |
| SCHEMBL8257613 | 0.80 | HSP90AB1 (0.62) | CYP11B1CYP11B2HSP90AB1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709712-A1 | GSK3A INHIBITORS AND METHODS OF USE THEREOF | Blueprint Medicines Corporation (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250059185-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2025-02-20 | — | — | US | disclosed |
| US-20250042896-A1 | POLYCYCLIC COMPOUND AS CBL-B INHIBITOR | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2025-02-06 | — | — | US | disclosed |
| EP-3653618-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-01-08 | — | — | EP | disclosed |
| WO-2024233900-A1 | GSK3A INHIBITORS AND METHODS OF USE THEREOF | BLUEPRINT MEDICINES CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240360134-A1 | PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2024-10-31 | — | — | US | disclosed |
| EP-4448522-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-10-23 | — | — | EP | disclosed |
| EP-3573974-B1 | RORGAMMA MODULATORS AND USES THEREOF | GENFIT (FR) | 2024-09-18 | — | — | EP | disclosed |
| US-20240270743-A1 | TETRAHYDROPYRAZOLOPYRIDINE-ANALOG LIGANDS OF NLRX1 AND USES THEREOF | LANDOS BIOPHARMA, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| CN-118488953-A | Bicyclic heterocyclic compounds useful as monoacylglycerol lipase inhibitors | 豪夫迈·罗氏有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-101094827-A | Benzene compound having two or more substituents | SANKYO CO (JP) | 2007-12-26 | — | — | CN | disclosed |
| US-20070154900-A1 | Methods for determining protein and peptide terminal sequences | TARGET DISCOVERY, INC (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1490043-A4 | SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO INC (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007024922-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007024922-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2007-03-01 | — | — | WO | disclosed |
| US-20050239828-A1 | Spirocyclic amides as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2005-10-27 | — | — | US | disclosed |
| EP-1490043-A2 | SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003082190-A2 | SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-10-09 | — | — | WO | disclosed |
| US-4921867-A | Pyridine compounds useful for therapy or prophylaxis of a disease associated with airway obstruction | GLAXO GROUP LIMITED (GB) | 1990-05-01 | — | — | US | disclosed |
| EP-0278728-A2 | 1-(4-Amino-3,5-dichlorophenyl)-2-(substituted amino)ethanol derivatives and their use in the treatment of respiratory disease | GLAXO GROUP LIMITED (GB) | 1988-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360134-A1 | PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS | PDGFRB, PDGFRA, ABL1 | CYP11B1 2653/4885CYP11B2 2243/4885HSP90AB1 1147/4885 |
| US-20240270743-A1 | TETRAHYDROPYRAZOLOPYRIDINE-ANALOG LIGANDS OF NLRX1 AND USES THEREOF | NLRP1, NLRP3, EPX | CYP11B1 3467/4885CYP11B2 3609/4885HSP90AB1 1761/4885 |
| US-20250059185-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, LIPC, PNLIP | CYP11B1 1841/4885CYP11B2 1702/4885HSP90AB1 1802/4885 |
| US-20250042896-A1 | POLYCYCLIC COMPOUND AS CBL-B INHIBITOR | CBLB, CBL, CBLC | CYP11B1 1841/4885CYP11B2 2120/4885HSP90AB1 3712/4885 |
| US-20050239828-A1 | Spirocyclic amides as cannabinoid receptor modulators | CNR1, CNR2, MAG | CYP11B1 486/4885CYP11B2 622/4885HSP90AB1 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.